BLOG

Saturday, October 6, 2018

Dr Reddy's seeks to revamp generics biz after remediation with USFDA flops

Sale of Bristol unit, downsizing staff, scaling down R&D and capex are some of the measures that compapny hopes will get it back to revenue growth and profitability

from Companies https://ift.tt/2OaMGe3
via IFTTT
at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO

However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...